{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+%28Healthy+Volunteers%29&page=2",
    "query": {
      "condition": "COVID-19 (Healthy Volunteers)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+%28Healthy+Volunteers%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T08:09:40.761Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05677893",
      "title": "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)"
      ],
      "interventions": [
        {
          "name": "MBS-COV",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Oneness Biotech Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2022-11-07",
      "completion_date": "2023-03-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-07-24T08:09:40.761Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05677893"
    },
    {
      "nct_id": "NCT04627675",
      "title": "CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "CORVax",
          "type": "DRUG"
        },
        {
          "name": "IL-12 plasmid",
          "type": "DRUG"
        },
        {
          "name": "Cliniporator",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2020-12-30",
      "completion_date": "2022-12-28",
      "has_results": true,
      "last_update_posted_date": "2024-10-26",
      "last_synced_at": "2026-07-24T08:09:40.761Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04627675"
    },
    {
      "nct_id": "NCT04452318",
      "title": "COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "REGN10933 + REGN10987",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Day and older"
      },
      "enrollment_count": 3303,
      "start_date": "2020-07-13",
      "completion_date": "2021-10-04",
      "has_results": true,
      "last_update_posted_date": "2023-05-15",
      "last_synced_at": "2026-07-24T08:09:40.761Z",
      "location_count": 132,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "La Palma",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04452318"
    },
    {
      "nct_id": "NCT04732468",
      "title": "COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "hAd5-S-Fusion+N-ETSD (Suspension for injection)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "hAd5-SFusion+ N-ETSD (Oral capsule)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2021-02-24",
      "completion_date": "2023-01-09",
      "has_results": true,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-07-24T08:09:40.761Z",
      "location_count": 2,
      "location_summary": "El Segundo, California • Newport Beach, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04732468"
    },
    {
      "nct_id": "NCT05280717",
      "title": "Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "sotrovimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 316,
      "start_date": "2022-03-28",
      "completion_date": "2023-11-06",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-07-24T08:09:40.761Z",
      "location_count": 10,
      "location_summary": "Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        },
        {
          "city": "Edgewater",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Binghamton",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05280717"
    },
    {
      "nct_id": "NCT05050682",
      "title": "Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-07304814",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 5,
      "start_date": "2021-10-07",
      "completion_date": "2021-12-10",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-07-24T08:09:40.761Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05050682"
    },
    {
      "nct_id": "NCT06146374",
      "title": "Safety Study of SLV213 for the Treatment of COVID-19.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Placebo for SLV213",
          "type": "OTHER"
        },
        {
          "name": "SLV213",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2024-04-09",
      "completion_date": "2024-07-08",
      "has_results": true,
      "last_update_posted_date": "2025-07-22",
      "last_synced_at": "2026-07-24T08:09:40.761Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06146374"
    },
    {
      "nct_id": "NCT05246878",
      "title": "A Study of EDP-235 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS CoV 2 Infection"
      ],
      "interventions": [
        {
          "name": "EDP-235",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enanta Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2022-01-28",
      "completion_date": "2022-07-20",
      "has_results": false,
      "last_update_posted_date": "2022-08-19",
      "last_synced_at": "2026-07-24T08:09:40.761Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05246878"
    },
    {
      "nct_id": "NCT04700163",
      "title": "RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "C144-LS and C-135-LS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2021-01-11",
      "completion_date": "2022-02-02",
      "has_results": true,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-07-24T08:09:40.761Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04700163"
    },
    {
      "nct_id": "NCT05216510",
      "title": "Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "TNX-2110",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TNX-2120",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TNX-2130",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CANDIN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diluent",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 9,
      "start_date": "2022-01-07",
      "completion_date": "2022-09-17",
      "has_results": true,
      "last_update_posted_date": "2024-11-06",
      "last_synced_at": "2026-07-24T08:09:40.761Z",
      "location_count": 1,
      "location_summary": "Berlin, New Jersey",
      "locations": [
        {
          "city": "Berlin",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05216510"
    }
  ]
}